Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J L Mahon

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Diabetes Care|August 11, 2000
Diabetes-related autoantibodies and the selection of subjects for trials of therapies to preserve pancreatic beta-cell function in recent-onset type 1 diabetesJ Dupré, J L Mahon
Diabetes Care|June 1, 1997
The limitations of clinical trials for prevention of IDDMJ L Mahon, J Dupre
Canadian Family Physician Medecin De Famille Canadien|January 26, 2011
The immunocompromised patientJ L Mahon, C R Stiller
Annals of the New York Academy of Sciences|November 30, 1993
Lessons learned from use of cyclosporine for insulin-dependent diabetes mellitus. The case for immunotherapy for insulin-dependent diabetics having residual insulin secretionJ L Mahon, J Dupre, C R Stiller
Annals of the New York Academy of Sciences|May 22, 2002
Autoantibodies and HLA susceptibility markers in Canadian first-degree relatives of patients with type 1 diabetesM T Behme, J L Mahon, J Dupre
Lancet (London, England)|April 15, 1995
Ethics of n-of-1 trialsJ L Mahon, B G Feagan, A Laupacis
Hormone Research|January 1, 1990
Induction and pathophysiology of remission of insulin-dependent diabetes mellitus during administration of ciclosporin. London Diabetes Study GroupJ Dupre, I Hramiak, J L Mahon, et al.
Diabetes Care|July 1, 1990
Immunosuppression in IDDM. Rationale, risks, benefits, and strategiesJ L Mahon, J Dupré, C R Stiller, et al.
Journal of Clinical Epidemiology|August 28, 1999
Surveying physicians to determine the minimal important difference: implications for sample-size calculationC van Walraven, J L Mahon, D Moher, et al.
American Journal of Hypertension|January 1, 1997
A randomized study comparing a patient-directed hypertension management strategy with usual office-based careK B Zarnke, B G Feagan, J L Mahon, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Diabetes Care|August 11, 2000
Diabetes-related autoantibodies and the selection of subjects for trials of therapies to preserve pancreatic beta-cell function in recent-onset type 1 diabetesJ Dupré, J L Mahon
Diabetes Care|June 1, 1997
The limitations of clinical trials for prevention of IDDMJ L Mahon, J Dupre
Canadian Family Physician Medecin De Famille Canadien|January 26, 2011
The immunocompromised patientJ L Mahon, C R Stiller
Annals of the New York Academy of Sciences|November 30, 1993
Lessons learned from use of cyclosporine for insulin-dependent diabetes mellitus. The case for immunotherapy for insulin-dependent diabetics having residual insulin secretionJ L Mahon, J Dupre, C R Stiller
Annals of the New York Academy of Sciences|May 22, 2002
Autoantibodies and HLA susceptibility markers in Canadian first-degree relatives of patients with type 1 diabetesM T Behme, J L Mahon, J Dupre
Lancet (London, England)|April 15, 1995
Ethics of n-of-1 trialsJ L Mahon, B G Feagan, A Laupacis
Hormone Research|January 1, 1990
Induction and pathophysiology of remission of insulin-dependent diabetes mellitus during administration of ciclosporin. London Diabetes Study GroupJ Dupre, I Hramiak, J L Mahon, et al.
Diabetes Care|July 1, 1990
Immunosuppression in IDDM. Rationale, risks, benefits, and strategiesJ L Mahon, J Dupré, C R Stiller, et al.
Journal of Clinical Epidemiology|August 28, 1999
Surveying physicians to determine the minimal important difference: implications for sample-size calculationC van Walraven, J L Mahon, D Moher, et al.
American Journal of Hypertension|January 1, 1997
A randomized study comparing a patient-directed hypertension management strategy with usual office-based careK B Zarnke, B G Feagan, J L Mahon, et al.
Pageof 2